#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 check­points are deeply en­trenched in the on­col­o­gy mar­ket, it’s time to wel­come a wave of com­bi­na­tion ther­a­pies — be­yond chemo — look­ing to ex­tend their ben­e­fit to larg­er num­bers of pa­tients. Bris­tol My­ers Squibb ($BMY} and Ex­elix­is {EX­EL} are close to the front of that line.

To­day at ES­MO the col­lab­o­ra­tors pulled the cur­tain back on some stel­lar da­ta for their com­bi­na­tion of Op­di­vo (the PD-1) and Cabome­tyx (the TKI), mark­ing a sig­nif­i­cant ad­vance for the block­buster Bris­tol My­ers fran­chise while of­fer­ing a big leg up for the team at Ex­elix­is.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER